Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2011-08-16
2011-08-16
Reddig, Peter J (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C424S193100, C424S278100, C530S300000, C530S350000
Reexamination Certificate
active
07998483
ABSTRACT:
The invention describes the LAGE-1 tumor associated gene, including fragments, allelic variants and splice variants thereof. Also included are polypeptides and fragments thereof encoded by such genes, and antibodies relating thereto. Methods and products also are provided for diagnosing and treating conditions characterized by expression of a LAGE-1 gene product.
REFERENCES:
patent: 5342774 (1994-08-01), Boon et al.
patent: 5405940 (1995-04-01), Boon et al.
patent: 5804381 (1998-09-01), Chen et al.
patent: 6140050 (2000-10-01), Sahin et al.
patent: 6251603 (2001-06-01), Jäger et al.
patent: 6252052 (2001-06-01), Stockert et al.
patent: 6274145 (2001-08-01), Chen et al.
patent: 6338947 (2002-01-01), Sahin et al.
patent: 6417165 (2002-07-01), Valmori et al.
patent: 6525177 (2003-02-01), Stockert et al.
patent: 6605711 (2003-08-01), Valmori et al.
patent: 6689742 (2004-02-01), Cerundolo et al.
patent: 6794131 (2004-09-01), Lethe et al.
patent: 7084239 (2006-08-01), Wang et al.
patent: 2346942 (2000-04-01), None
patent: 1001022 (2000-05-01), None
patent: 1121435 (2001-08-01), None
patent: 2002527109T (2002-08-01), None
patent: WO 96/10577 (1996-04-01), None
patent: WO 98/14464 (1998-04-01), None
patent: WO 00/23584 (2000-04-01), None
Kirkin et al, 1998, APMIS, 106 : 665-679.
Mellman, 2006, The Scientist, 20(1): 47-56.
Bodey et al, 2000, Anticancer Res, 20: 2665-2676.
Lee et al, 1999, J Immunol, 163: 6292-6300.
Aarnoudse C.A., “Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1,”Int J Cancer., Jul. 30, 1999; 30;82(3):442-8.
Alberts et al., Mol. Bio. Cell 1994; 3rded., p. 465.
Ausubel, F.M. et al., eds. Current protocols in molecular biology, 1987; John Wiley & Sons, New York, pp. 6.3.5.
Boon, Adv. Cancer Res. 1992; 58:177-210.
Bork, Genome Research 2000; 10:398-400.
Bowie et al, Science 1990; 257:1306-1310.
Burgess et al., J. of Cell Biol. 1990; 111:2129-2138.
Chen, et al., “A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening,” Proc. Nat'l. Acad. Sci. USA vol. 94 pp. 1914-1918 (Mar. 1997).
Coulie et al., Stem Cells 13:393-403, (1995).
Crystal, Science 1995; 270:404-410.
De Plaen et al., Immunogenetics 40:360-369, (1994).
Deonarain, Expert Opin. Ther. Pat. 1998; 8:53-69.
Ezzel, J. NIH Res. 1995; 7:46-49.
Fu et al., EMBO J 1996; 15(16):4392-4401.
Gillies, Human Antibod. Hybridomas 1990; 1(1):47-54.
Greenbaum et al., Genome Biology 2003; vol. 4, issue 9, pp. 117.1-117.8.
Greenspan, Nature Biotech. 1999; 7:936-937.
Guo et al., Journal of Pharmacology and Experimental Therapeutics 2002; 300:206-212.
Hell et al., Laboratory Investigation 1995; 73:492-496.
Hillier, EMBL Database, Accession No. AA634317 (Oct. 1997).
Hubank and Schatz, Nucl. Acids Res. 22:5640, (1994).
Hubert, The Dict. Immunol. 1995; AP, 4thed., pp. 55.
Jansen, M. et al., Pediatric Res. 1995; 37(6):681-686.
Kirkin et al., APMIS 1998; 106:665-679.
Lazar et al., Molecular and Cellular Biology 1988; 8:1247-1252.
Lethe B. et al, “LAGE-1, a new gene with tumor specificity,”Int J Cancer., Jun. 10, 1998; 76(6):903-8.
Mandic M. et al. “The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells,”Cancer Res., Oct. 1, 2003; 63(19):6506-15.
McClean, Eur. J. Cancer 1993; 29A:2243-2248.
Miller, FASEB J. 1995; 9:190-199.
MPSRCH search report, 2006, US-10-877.373.5.rai., pp. 11-12.
MPSRCH search report, 2008, US-10-877-373.5.rai. result 15, pp. 1-2.
MPSRCH search result, 2006, US-10-877-373-5.iligo.rai, result 9, p. 1.
Odunsi K. et al., “NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer,”Cancer Res., Sep. 15, 2003; 63(18):6076-83.
Rammensee, et al., Immunogenetics 41:178-228 (1995).
Reigrer, Glossary of Genetics Cytogenetics 1976; Classical Mol. 4thed., Springer-Verlay Berlin, p. 17.
Rimoldi D. et al., “Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma,”J Immunol., Dec. 15, 2000; 165(12):7253-61.
Sambrook et al., eds, 1989; Molecular cloning, a Laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, p. 14.2-14.4.
Scott et al., Nature Genetics 1999; 21:440-443.
Shantz, L.M., Int.'l J. Biochem. Cell Biol. 1999; 31:107-122.
Sharma P. et al., “Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer,”Cancer Immun., Dec. 18, 2003; 3:19.
Slager E.H. et al., “CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame,”J Immunol., Feb. 1, 2003; 170(3):1490-7.
Smith, R.T., Clin. Immunol. 1994; 41(4):841-849.
Spitler, Cancer Biotherapy 1995; 10:1-3.
Toa, Immunol. 1989; 143(8):2595-2601.
Traversari, et al., Immunogenetics 1992; 35:145.
Usener D. et al., “Seroreactivity against MAGE-A and LAGE-1 proteins in melanoma patients,”Br J Dermatol., Aug. 2003; 149(2):282-8.
Van Den Eynde, et al., Curr. Opinion in Immun. 1995; 7:674-681.
Van Der Bruggen, et al. Science 254:1643-1647 (1991).
Verma, Nature Sep. 1997; 389:239-242.
White et al., Ann. Rev. Med. 2001; 52:125-145.
Yokota, J. et al., Oncogene 1988; 3:471-475.
Zimmer, Cell Motility and the Cytoskeleton 1991; 20:325-337.
Boon-Falleur Thierry
De Smet Charles
Godelaine Daniele
Lethe Bernard
Lucas Sophie
Ludwig Institute for Cancer Research Ltd.
Reddig Peter J
Wolf Greenfield & Sacks P.C.
Xiao Yan
LandOfFree
Lage-1 tumor associated nucleic acids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lage-1 tumor associated nucleic acids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lage-1 tumor associated nucleic acids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2662287